OLR1 and Stroke: In summary, a more detailed analysis of the molecular pathways crucial for the increase of sLOX-1 in cardiovascular disease in combination with large-scale clinical studies is required to further establish this receptor fragment as early biomarker for CAD, ACS, AAD, and stroke.